AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Equities researchers at Svb Leerink raised their FY2019 earnings estimates for shares of AMAG Pharmaceuticals in a research report issued to clients and investors on Sunday, June 23rd, Zacks Investment Research reports. Svb Leerink analyst A. Fadia now anticipates that the specialty pharmaceutical company will earn ($2.79) per share for the year, up from their previous forecast of ($2.80). Svb Leerink also issued estimates for AMAG Pharmaceuticals’ Q4 2019 earnings at ($1.00) EPS, FY2020 earnings at ($2.19) EPS, FY2021 earnings at ($0.45) EPS, FY2022 earnings at $0.78 EPS and FY2023 earnings at $0.66 EPS.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($2.77). AMAG Pharmaceuticals had a negative net margin of 30.90% and a negative return on equity of 26.33%. The firm had revenue of $75.80 million during the quarter, compared to the consensus estimate of $90.13 million. During the same period in the prior year, the business posted ($1.59) earnings per share. AMAG Pharmaceuticals’s quarterly revenue was down 35.4% compared to the same quarter last year.
Shares of NASDAQ:AMAG traded up $0.35 during midday trading on Wednesday, hitting $9.00. The stock had a trading volume of 2,456,100 shares, compared to its average volume of 783,608. AMAG Pharmaceuticals has a 12 month low of $7.81 and a 12 month high of $26.10. The company has a current ratio of 2.30, a quick ratio of 2.13 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average of $9.46. The firm has a market capitalization of $288.35 million, a P/E ratio of -2.32 and a beta of 0.47.
Several institutional investors and hedge funds have recently bought and sold shares of AMAG. Pearl River Capital LLC acquired a new stake in shares of AMAG Pharmaceuticals during the fourth quarter worth $28,000. NumerixS Investment Technologies Inc lifted its holdings in shares of AMAG Pharmaceuticals by 17.8% during the first quarter. NumerixS Investment Technologies Inc now owns 7,166 shares of the specialty pharmaceutical company’s stock worth $90,000 after buying an additional 1,083 shares in the last quarter. Municipal Employees Retirement System of Michigan acquired a new stake in shares of AMAG Pharmaceuticals during the fourth quarter worth $151,000. Metropolitan Life Insurance Co. NY lifted its holdings in shares of AMAG Pharmaceuticals by 361.9% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 12,656 shares of the specialty pharmaceutical company’s stock worth $192,000 after buying an additional 9,916 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund acquired a new stake in shares of AMAG Pharmaceuticals during the fourth quarter worth $200,000.
In related news, insider Elizabeth Scott Bolgiano acquired 5,000 shares of AMAG Pharmaceuticals stock in a transaction on Thursday, May 9th. The stock was purchased at an average cost of $10.93 per share, with a total value of $54,650.00. Following the completion of the transaction, the insider now directly owns 74,847 shares in the company, valued at approximately $818,077.71. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Armistice Capital, Llc bought 259,016 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were purchased at an average cost of $8.59 per share, with a total value of $2,224,947.44. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 328,016 shares of company stock valued at $2,904,577. Company insiders own 4.90% of the company’s stock.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Featured Story: Return On Assets
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.